PTPN11 and neuroblastoma: Currently, there is a significant interest in identifying aberrant signaling pathways and RAS/MAPK activating mutations, like those of PTPN11 and FGFR1 genes detected in the present case, that could be therapeutically targeted for relapsing NB.